Nuvectis Pharma
NVCT
11 hedge funds and large institutions have $7.38M invested in Nuvectis Pharma in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
2.96% less ownership
Funds ownership: 9.68% → 6.72% (-3%)
8% less funds holding
Funds holding: 12 → 11 (-1)
27% less capital invested
Capital invested by funds: $10M → $7.38M (-$2.67M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.21M |
| 2 |
VF
Virtu Financial
New York
|
+$88.9K |
| 3 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$2.15K |
| 4 |
Morgan Stanley
New York
|
+$716 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$86 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$326K |
| 2 |
BlackRock
New York
|
-$27.5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$19.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $4.41M | -$326K | -45,527 | -7% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $1.47M | +$1.21M | +168,768 | +624% |
|
|
BWP
3
Baldwin Wealth Partners
Marion,
Massachusetts
| $1,000K | +$2.15K | +300 | +0.2% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $235K | -$523 | -73 | -0.2% |
|
|
VF
5
Virtu Financial
New York
| $93K | +$88.9K | +12,418 | New |
|
6
State Street
Boston,
Massachusetts
| $87.9K | – | – | – |
|
|
7
BlackRock
New York
| $76.2K | -$27.5K | -3,842 | -27% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $10K | -$19.3K | -2,693 | -66% |
|
|
9
Morgan Stanley
New York
| $2.26K | +$716 | +100 | +50% |
|
10
Wells Fargo
San Francisco,
California
| $188 | +$7 | +1 | +4% |
|
|
11
Bank of America
Charlotte,
North Carolina
| $90 | +$86 | +12 | New |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$2K | -220 | Closed |
|
|
13
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -76 | Closed |
|
NVCT Hedge Fund Activity: Q4 2022 in Review
11 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q4 2022, worth a combined $7.38M — down 27% from $10M a quarter earlier.
Fund positioning in NVCT was balanced in Q4 2022: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.21M. The largest seller was Sabby Management, cutting an estimated $326K.
- 11 institutional investors held Nuvectis Pharma (NVCT) as of Q4 2022, down from 12 in Q3 2022.
- Funds reported $7.38M of Nuvectis Pharma stock for Q4 2022, down 27% quarter-over-quarter.
- 2 funds opened new Nuvectis Pharma positions in Q4 2022 and 2 closed out, a net change of 0 holders.
- The largest Nuvectis Pharma buyer in Q4 2022 was Vanguard Group, an estimated $1.21M added.
- The largest Nuvectis Pharma seller in Q4 2022 was Sabby Management, an estimated $326K sold.
Based on aggregated 13F filings for Q4 2022.